Prelude Therapeutics (PRLD) announced a significant strategic partnership and financing event with Incyte on November 3, 2025, centered around Prelude’s mutant selective JAK2V617F inhibitor program for Myeloproliferative Neoplasms (MPNs).
Strategic Partnership & Financing: Prelude entered an exclusive option agreement and a securities purchase agreement with Incyte. Immediate capital totals \(60 million, comprising a \)35 million upfront cash payment and a \(25 million equity investment (\)4.00 per share for 6.25 million non-voting shares). The deal structure allows Incyte to acquire the MPN
...